Recombinant Human PCSK9 Protein, C-AVI tagged, Biotinylated

• Cat.No.: PCSK9-33H
• Product Overview: Recombinant Human Proprotein Convertase 9 is produced by our Mammalian expression system and the target gene encoding Gln31-Gln692 is expressed with a AVI tag at the C-terminus.

Specification

• Description: Human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is a secretory subtilase belonging to the proteinase K subfamily. PCSK9 is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the ER, the pro domain and mature chain secrete together through noncovalent interactions. PCSK9 binds with low-density lipoprotein receptor (LDLR) and plays a major regulatory role in cholesterol homeostasis. Inhibition of PCSK9 function by preventing PCSK9/LDLR interaction is currently being explored as a means of lowering cholesterol levels. PCSK9 also binds to apolipoprotein receptor 2 (ApoER2), and play a role in the neural development.
• Source: Human Cells
• Species: Human
• Tag: Avi
• Protein length: Gln31-Gln692(Val474Ile, Gly670Glu)
• Endotoxin: Less than 0.1 ng/μg (1 EU/μg)
• Storage Buffer: Supplied as a 0.2 μm filtered solution of 50 mM HEPES, 150 mM NaCl, pH 7.4.
• Shipping: Dry ice/Polar packs

Gene Information

• Gene Name: PCSK9 proprotein convertase subtilisin/kexin type 9 [ Homo sapiens (human) ]
• Official Symbol: PCSK9
• Synonyms: Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1
• Gene ID: 255738
• mRNA Refseq: NM_174936
• Protein Refseq: NP_777596
• MIM: 607786
• UniProt ID: Q8NBP7

Reviews

11/13/2022

In immunological experiments, it was found that it had good antigenicity and could induce target immune responses.

07/07/2022

It promoted cell growth and proliferation.

03/04/2022

High catalytic efficiency.

Q&As

Is there a relationship between genetic mutations in the PCSK9 protein and cardiovascular disease?

Yes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.

How can PCSK9 protein be used for vaccine development?

PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.

What is the relationship between PCSK9 protein and obesity?

This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.

What are the new prospects for future therapies that inhibit PCSK9 protein?

Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.

What drugs are currently available to inhibit the PCSK9 protein?

Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.

What is the relationship between PCSK9 protein and hypercholesterolemia?

PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.